Vortosiran

Asset

Silences hepatic factor XI expression to reduce coagulation and thromboembolic risk.

Stage: Phase 2
Modality: Oligonucleotide
Target: F11; 1
Indication: 1
Trial: 1
Developer

Indications

1

Non-valvular atrial fibrillation
Phase 2, Not yet recruiting, NCT07870889, clinicaltrials.gov, 15 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials1
Evidence for its targets1
Competitors2
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.